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Androgen receptorSpinal and bulbar muscular atrophy (SBMA, Kennedy's disease) is a motor neuron disease caused by
polyglutamine repeat expansion in the androgen receptor. Although degeneration occurs in the spinal cord
and muscle, the exact mechanism is not clear. Induced pluripotent stem cells from spinal and bulbar muscular
atrophy patients provide a useful model for understanding the disease mechanism and designing effective ther-
apy. Stem cells were generated from six patients and compared to control lines from three healthy individuals.
Motor neurons from four patients were differentiated from stem cells and characterized to understand
disease-relevant phenotypes. Stem cells created from patient ﬁbroblasts express less androgen receptor than
control cells, but show androgen-dependent stabilization and nuclear translocation. The expanded repeat in
several stem cell clones was unstable, with either expansion or contraction. Patient stem cell clones produced
a similar number of motor neurons compared to controls, with or without androgen treatment. The stem cell-
derived motor neurons had immunoreactivity for HB9, Isl1, ChAT, and SMI-32, and those with the largest repeat
expansions were found to have increased acetylated α-tubulin and reduced HDAC6. Reduced HDAC6 was also
found in motor neuron cultures from two other patients with shorter repeats. Evaluation of stably transfected
mouse cells and SBMA spinal cord showed similar changes in acetylatedα-tubulin and HDAC6. Perinuclear lyso-
somal enrichment, an HDAC6 dependent process, was disrupted in motor neurons from two patients with the
longest repeats. SBMA stem cells present new insights into the disease, and the observations of reduced androgen
receptor levels, repeat instability, and reduced HDAC6 provide avenues for further investigation of the disease
mechanism and development of effective therapy.
Published by Elsevier Inc.Introduction
Our understanding of the pathogenesis of motor neuron disease has
been limited by the paucity of model systems that can recapitulate
disease features as they occur in vivo. SBMA is caused by a CAG repeat
expansion in the androgen receptor (AR) gene on the X chromosome
(La Spada et al., 1991), which results in polyglutamine expansion andstosterone; EtOH, ethanol; iPSC,
uscular atrophy.
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SBMA patients have repeat lengths between 38 and 62 CAGs; whereas
normal individuals have between 5 and 36 CAGs (Atsuta et al., 2006;
Rhodes et al., 2009). The length of the CAG repeat correlates inversely
with the age of disease onset,with longer repeats associatedwith earlier
onset. The affected males have a slowly progressive deﬁcit with weak-
ness of the limb and bulbar muscles due to lower motor neuron and
muscle degeneration. There is currently no treatment available to affect
the progression of this disease, and although cellular processes such as
transcriptional regulation (Nedelsky et al., 2010), mitochondrial func-
tion (Ranganathan et al., 2009), and axonal transport (Katsuno et al.,
2006) have been implicated, the precise mechanism underlying the
pathology is not clear.
The induced pluripotent stem cell (iPSC) system provides a unique
opportunity in which stem cells can be generated from adult patients
and then differentiated into disease-relevant progeny such as neurons,
glia, and muscle. This technology has been used to generate and differ-
entiate iPSCs from patients with motor neuron diseases such as ALS
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cells differentiated from spinal muscular atrophy (SMA) iPS cells
(Ebert et al., 2009). An assay for screening small molecules in such a
system may also be expected to yield more disease-relevant results,
since it is human patient-derived. Motor neuron-like cells derived
from ALS patients with mutations in TDP-43 have been used to screen
candidate chemical compounds (Egawa et al., 2012). These systems
offer the potential advantage of reproducing the cellular and molecular
features of the disease, with physiological levels of mutant protein
expression. Additional insights into the disease mechanism may
provide new targets for therapeutic development.
In this study we generated lines from six SBMA patients, and per-
formed a detailed evaluation of lines from four different patients and
three controls. The SBMA iPSCs retain the CAG repeat expansion present
in the parentalﬁbroblasts, and in some cases variation from the parental
CAG repeat length was observed. We found that the AR is expressed in
the undifferentiated iPSCs, and able to translocate to the nucleus in
response to ligand treatment. The iPSC lines were differentiated into
motor neurons, and further characterization of these cells was done.
Motor neuron derivatives from the SBMA iPSCs were found to have a
reduction in HDAC6. The iPSCs described here are valuable tools
for understanding the disease process, and they provide a system for
evaluating candidate treatments.
Materials and methods
iPSC generation
Lentiviral vectors containing the polycistronic transcripts Oct4, Klf4,
Sox2, and c-Myc (Sommer et al., 2009) were purchased from Millipore
(Billerica, MA) and Stemgent (Cambridge, MA). Human ﬁbroblasts
were seeded at 2.5 × 104 cells/well on a 6-well plate. For the next two
days theﬁbroblastswere transducedwith virus and plated onto a feeder
layer of mitomycin-c treated MEF cells at day 6. Colonies with hESC
morphology were mechanically dissociated after three weeks. Sendai
virus was purchased from Invitrogen (Carlsbad, CA) and used according
to the manufacturer's instructions. Episomal vectors were purchased
from Addgene (Cambridge, MA) and cotransfected into ﬁbroblasts
using the U-20 Amaxa nucleofection program (Walkersville, MD).
After expansion, the iPSCs were maintained in mTESR media (Stem
Cell Technologies, Vancouver, Canada).
CAG repeat sizing
Polymerase chain reaction (PCR) was performed using Taq
polymerase-containing master mix (FastStart PCR Master; Roche,
Basel, Switzerland), with 20 nM forward and reverse primers
(5′-TCCAGAATCTGTTCCAGAGCGTGC-3′ and 5′-GCTGTGAAGGTTGCTG
TTCCTCAT-3′, respectively). PCR products were analyzed on a 20%
Tris–borate–EDTA gel (Invitrogen). The Big Dye cycling protocol
(Invitrogen) was performed using a two step method without the
annealing step (96 °C 10 s, 60 °C 4 min).
Motor neuron differentiation
Differentiation was performed as previously described (Amoroso
et al., 2013). Brieﬂy, iPSCswere grown to 80% conﬂuency, then digested
with collagenase IV (Invitrogen) for 8 min. Cells were scraped off of the
dish, and after settling the supernatant was aspirated, and cells were
re-plated into low adherence dishes (Corning, Corning, NY) in KSR
(Invitrogen) basedmediawith 20 ng/ml FGF (R+D Systems,Minneap-
olis, MN), 20 μM ROCK-I (Tocris, Bristol, UK), 10 μM SB431542 (Tocris),
and 0.2 μM LDN193189 (Stemgent). Embryoid bodies (EBs) were
transitioned to a KSR free medium after 3 days. Retinoic acid was
added to the media after 5 days to direct the cells towards a rostral spi-
nal cord phenotype, with additional patterning using 1 μM smoothenedagonist (Calbiochem, Billerica, MA) and 0.5 μM purmorphamine
(Stemgent) after 7 days to ventralize the differentiating population.
After 14–16 days in suspension, the EBs were dissociated and plated on
dishes coated with polyornithine or poly-D-lysine and laminin for an ad-
ditional 7–14 days. Neuronal cultures were maintained in neurobasal
media (Invitrogen) with 25 μM glutamate (Sigma, St. Louis, MO),
0.4 μg/ml ascorbic acid (Sigma), 10 ng/ml GDNF (Sigma), 10 ng/ml
CNTF (Sigma), 1 μg/ml laminin (BD Bioscience, Franklin Lakes, NJ).
B-27, N2, non-essential amino acids, and pen/strep/glutamine were all
from Invitrogen. Two days after plating 10 nM dihydrotestosterone
(DHT) was added, and the cultures were maintained for an additional
7–14 days.
Immunoblotting
Cell pellets were lysed with RIPA buffer [150 mM NaCL, 1% NP40,
0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris pH 8.0 and Protease
inhibitor cocktail (Roche)] and allowed to stand on ice for 20min before
being centrifuged at 4 °C at 20,000 g for 20 min. Supernatant was col-
lected and protein levels were measured using a Bio-Rad (Hercules,
CA) protein assay. Membranes were blocked with a 5% milk solution
and incubated in milk with primary antibody overnight. The antibodies
used were AR H280 and AR N20 (Santa Cruz Biotech., Santa Cruz, CA),
GAPDH (EnCor Biotechnology, Gainesville, FL), ChAT (Millipore),
MNX1/HLXB9 (Novus, Littleton, CO), HDAC6 D2E5 and LAMP1 (Cell
Signaling, Danvers, MA). Stacking gel analysis for aggregation analysis
was performed on supernatant samples prepared after centrifugation
at 4 °C for 10 min at 425 g. PNGaseF was purchased from New England
Biolabs (Ipswich,MA), and treatmentswere performed for 3 h using the
manufacturer's guidelines.
Immunohistochemistry
After ﬁxation with 4% paraformaldehyde, slides were placed in
blocking solution (10% normal goat serum, 0.3% Triton X-100, in phos-
phate-buffered saline (PBS)) for 45 min at room temperature. Primary
antibody staining was done at 4 °C overnight in PBS with 5% normal
goat serum and 0.1% Triton X-100 using Oct-3/4 (Santa Cruz), GSK-3β
Phospho Ser9 (Cell Signaling), AR H280 and N20 (Santa Cruz), Tra-1-60,
1C2, and Chat (Millipore), Isl1 and HB9 (DSHB, Iowa City, IA), SMI 32
and β-tubulin (Covance, Princeton, NJ), HDAC6 and LAMP1 (Cell Signal-
ing), and acetylated tubulin and neuroﬁlament (Sigma). Slides were
thenwashed three timeswith PBST (0.1% TritonX-100 in PBS), incubated
with secondary antibody (Invitrogen, 1:500) for 1 h at room temperature
in the dark, and then washed three times before drying and adding
vectashield/DAPI stain (Vector Lab, Burlingame, CA). For AR staining in
motor neurons, slides were treated with 100 mM glycine after ﬁxation,
and blocked in PBS with 3% bovine serum albumin (BSA). Antibody
staining was performed in PBS with 3% BSA and 0.1% Tween with
0.1% Tween/PBS used for all washes. Coverslips were mounted with
permamount (Thermo, Waltham, MA).
Results
Derivation and characterization of iPSC from SBMA patients and controls
IPSC lines were derived using forearm ﬁbroblasts from six SBMA
patients (SB1, 3, 6, 15, 17, and 18) and three healthy control adults
(NC4, 7, and 15) (Table 1). All iPSC lines chosen for evaluation had ex-
pression of pluripotency markers by immunostaining and quantitative
PCR (Fig. S1). Karyotype analysis was normal in 12 clones tested, from
which 5 patient (Fig. 1, asterisks) and 3 control lines were chosen for
further analysis. Down-regulation of Oct4 was observed in the motor
neuron derivatives from the iPSC, showing sufﬁcient down regulation
of the polycistronic vector. Teratoma analysis was done for the
SB6MP2 clone.
Table 1
iPS lines used.
iPS line NC4 NC7 NC15 SB1 SB3 SB6 SB15 SB17 SB18
Age of onset N/A N/A N/A 39 53 32 34 25 18
Age 31 23 51 59 68 37 49 43 29
Sex Male Male Female Male Male Male Male Male Male
Reprogramming
method
Millipore
Lentivirus
Millipore
Lentivirus
Millipore
Lentivirus
Stemgent
Lentivirus
(all)
Millipore
Lentivirus
(all)
Millipore Lentivirus (clones
1 + 2).
Episomal (clone #3)
Sendai
virus
(all)
Millipore
Lentivirus
(all)
Millipore
Lentivirus
(all)
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and Sanger sequencing. Several of the iPSC clones showed differences in
the repeat size in comparison to the parental ﬁbroblasts (Fig. 1). This
difference was most striking for the SB6 iPSC clones, which increased
by six CAGs from 56 CAGs in the ﬁbroblasts to 62 CAGs in the three
iPSC clones evaluated. iPSCswith shorter CAG lengths than the parental
ﬁbroblast were found with Sendai virus reprogramming in the SB15
lines, with two of the lines having four fewer CAGs. With subsequent
passaging the repeat region was stable in the three lines evaluated.
CAG length remained the same between the parental ﬁbroblasts and
iPSCs in all three control lines evaluated (data not shown).
Androgen receptor expression in iPSCs
To determine whether SBMA iPSCs have the capacity to develop
phenotypic abnormalities, we ﬁrst evaluated undifferentiated cells for
AR expression and localization. Expression and nuclear translocation
of the AR in response to ligand (DHT) treatment were observed in the
3 control and 4 SBMA iPSC lines evaluated (Fig. 2A, the SBMA lines
used are labeled by an asterisk in Fig. 1). Although the mutant AR has
been observed to form inclusions in patient tissue and other cellular
models of SBMA, inclusions were not detected in the SBMA iPSCs. We
assayed for inclusions by immunostaining iPSCs and their derivatives
for the androgen receptor and polyglutamine repeat motif (1C2 anti-
body), as well as western blotting of extracts including the stacking
portion of an acrylamide gel (Fig. S4).
We next compared the AR expression levels in the iPSCs to ﬁbro-
blasts. Human control and SBMA ﬁbroblasts had a similar response to
DHT as found in iPSCs (Fig. 2B). SBMA iPSC lines had signiﬁcantly
lower AR levels (p b 0.001) than the control lines, and this difference
was also present after DHT treatment for 48 h (p b 0.001). AR mRNA
expression in SBMA and control cells did not show a difference with
either vehicle or DHT. These observations suggest that the AR behaves
similarly in iPSCs as in other cell systems, and that the level of AR
protein in SBMA iPSCs is reduced compared to control lines.
Motor neuron differentiation and characterization
Since motor neuron degeneration is one of the characteristic fea-
tures in SBMA, we sought to differentiate the iPSCs into a motor neuron
lineage using an established protocol (Amoroso et al., 2013) (Fig. 3A).
Within one day of dissociation, control and SBMA cells extended
processes. Two days after plating, fresh neuronal culture media was
added with either vehicle or DHT, and the cells were then cultured for
10 days. Immunostaining for the motor neuron markers HB9 and Isl1
showed approximately 20–30% positive cells. There was no signiﬁcant
difference in the number of motor neurons generated between control
and patient iPSCs with either vehicle or DHT (Fig. 3B). However, cul-
tures from the SB18 patient line had approximately 14%motor neurons
compared to an average of 24% for the other SBMA lines. The processes
in both sets of cultures had positive staining for β-tubulin and SMI-32,
markers expressed in primary motor neurons and corticospinal tract
neurons (Fig. S2). Immunostaining showed that the AR is expressed in
the motor neurons, although the relative amount of expression in
some motor neurons was less than in other non-motor neuron cells
within the same culture, as shown by the arrows in Fig. 3C. NuclearAR staining was also seen in the absence of DHT (Fig. 3C), although
increased levels were observed after DHT treatment in both control
and SBMA cultures (Fig. 4D).
We found increased staining for acetylated α-tubulin in several of
the SBMA iPSC clones (Fig. 4A). Although this was occasionally seen in
the SB3 and SB1 lines, it was most consistent in the SB6MP2 and
SB6MP3 clones, which both contain 62 CAGs. Staining for othermarkers
of the processes, including neuroﬁlament, was similar between SB6 and
control lines.Motor neuron derivatives from the SB18 linewith 68 CAGs
were also found to have increased acetylated tubulin (Fig. S3). There
was no appreciable difference in the extent of acetylation with DHT
treatment, and all immunostaining images of cells under these condi-
tions are shown with vehicle only.
As HDAC6 is one of the major deacetylating enzymes for α-tubulin,
we sought to evaluate the levels of HDAC6 in our control and SBMA
motor neuron cultures. Immunostaining for HDAC6 showed cytoplas-
mic localization, and the motor neurons had higher levels than other
cells in the culture (Figs. 4C, S3). HDAC6 levels in several SBMA lines
were reduced compared to controls, p b 0.001. HDAC6 levels were
adjusted based on the total level of HB9 and Isl1 staining. Western
blot analysis across the control and SBMA iPSCs also showed a reduction
in HDAC6 levels, with comparable amounts of ChAT and HB9 detected.
As GSK-3β inhibition is known to decrease HDAC6 levels, we evaluated
the degree of GSK-3β activation by immunostaining for the inactive
form of GSK-3β (Ser9) and found comparable levels in SBMA and
control motor neurons.
We next sought to determine whether tubulin and HDAC6 are sim-
ilarly altered in another cell model system of SBMA and patient tissue.
We assessed murine motor neuron-neuroblastoma (MN1) cells stably
transfected with human AR containing either 24 or 65 CAGs (Brooks
et al., 1997). After 48 h of DHT treatment, the cells were evaluated for
HDAC6 and acetylated α-tubulin by immunostaining and western blot
(Fig. 5A). The MN1 cells with the unexpanded CAG repeat have abun-
dant cytoplasmic HDAC6 and reduced staining for acetylated tubulin,
whereas the MN1 clone with expanded 65Q AR had reduced HDAC6
levels and increased levels of acetylated tubulin (p = 0.03) after DHT
treatment. A similar pattern was also observed in the ventral horn of
the spinal cord of a control subject and a patient showing that the
patient tissue had increased staining for acetylated α-tubulin and
reduced motor neuron staining for HDAC6 (Fig. 5B).
Sincemicrotubule-mediated transport of intracellular organelles can
be disrupted by HDAC6 deﬁciency (Iwata et al., 2005), we analyzed the
location of lysosomes in the motor neuron derivatives. Staining for the
lysosomal marker LAMP1 in the control motor neurons showed enrich-
ment of staining around the microtubule organizing center (Fig. 6A).
LAMP1 staining in the motor neuron cultures from the SB6 and SB18
SBMA iPSC lines with the largest CAG repeats showed more diffuse
staining around the nucleus. Western blot analysis of the motor neuron
extracts for LAMP1 showed increasedmolecular weights in the SB6 and
SB18 patient lines with or without DHT (Fig. 6B). These changes in
LAMP1 molecular weight were not detected in the undifferentiated
DHT-treated iPSCs (Fig. 6C). Since LAMP1 is known to be heavily glyco-
sylated, we removed the N-glycans by PNGaseF treatment and analyzed
the samples for LAMP1. Western blot showed bands of similar molecu-
lar weight in all samples with the predominant bands at 40 and 42 kDa
(Fig. 6D).
Fig. 1. Expansion and contraction of CAG polyglutamine repeat during the induction of
pluripotency. Polyacrylamide gels show changes in CAG repeat length in different colonies
from multiple iPSC lines. F refers to the ﬁbroblast sample from which the iPSCs were
derived. The asterisk notation refers to those patient lines that were chosen for further
analysis of AR expression and differentiation.
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We generated iPSCs from SBMA patients in order to characterize
phenotypic features that can be used to elucidate the disease mecha-
nism. Although the AR is expressed in many tissues, it is not clear why
certain cells are vulnerable in the disease, such as anterior horn cells,
dorsal root ganglion cells, and skeletal muscle (Iwata et al., 2005;
Kennedy et al., 1968). At present there is no treatment to slow the
disease progression, and better understanding of the pathogenesis
may help in identifying therapeutic targets.
Patient-derived iPSCs grow and differentiate like human embryonic
stem cells. Although SBMA iPSC clones generally have CAG repeat
lengths similar to the parental ﬁbroblasts, we have identiﬁed clones
with CAG repeat lengths that are longer or shorter. The differences in
iPSC repeat length could be due to repeat instability during the cloning
or to repeat length mosaicism in the parental ﬁbroblast population.
Repeat instability occurs between generations in patients, more
frequently during transmission of the mutant allele from father to
daughter (Zhang et al., 1994). It is possible that chromatin remodeling
during reprogramming recapitulates processes similar to those that
take place during meiosis and gametogenesis (Xu et al., 2011). Somatic
mosaicism has also been observed in polyglutamine diseases (Tanaka
et al., 1999), and it is also conceivable that mosaicism within the ﬁbro-
blast population results in clonal expansion of different CAG repeat sizes
represented in the ﬁbroblast pool. This may explain some of the smaller
differences in repeat size, but it is less likely to be present in the clones
which more consistently have substantial variation from the parental
ﬁbroblasts, such as the clones from the SB6 ﬁbroblasts. In a previous
study of SBMA iPSCs (Nihei et al., 2013), the CAG repeat length was
unchanged in two clones from one patient and, as with our lines, stable
with long term passaging.
Our ﬁndings show that the AR is expressed in iPSCs and undergoes
nuclear translocation as in other cells expressing AR. The level of AR
is increased with ligand (DHT) treatment at the protein level only,suggesting that the increased level is a result of protein stabilization,
as has been shown in other cell lines (Furutani et al., 2002). The AR ap-
pears to be expressed at equal or higher levels in all of the iPSCs evalu-
ated compared to human ﬁbroblasts, as assessed by both quantitative
PCR and western blotting. This ﬁnding is in contrast to the previous
iPSC study which showed that AR protein levels in iPSCs were negligi-
ble, and reduced compared to ﬁbroblasts (Nihei et al., 2013). The reason
for this discrepancy is not clear, however, it may be due in part to
differences in cell culture technique.
The ﬁnding of reduced AR protein levels in the SBMA iPSCs was
reproduced in lines from four patients compared to three controls.
This difference was detected with and without DHT, and appeared to
occur at the protein level, since AR mRNA levels were roughly equal.
This differencewas detectedwhen the cells were cultured in two differ-
ent types of media, mTeSR and E8. It is possible that selective pressure
led to the expansion and growth of SBMA iPSC colonies that had re-
duced AR levels. If selective pressure occurs, then this may reﬂect toxic-
ity of themutant AR in the SBMA iPSCs, perhaps during reprogramming.
It is possible that the SBMA iPSCs are similar to controls in other ways
because of compensatory down-regulation in AR levels. We have not
detected any abnormality in the survival of the SBMA iPSCs after main-
taining the cells with DHT for ﬁve passages. However, it is possible that
treatment with additional factors to stabilize the mutant AR would
induce overt toxicity in the undifferentiated SBMA iPSCs. It does not
appear that the AR protein reduction is dependent on the length of
the CAG repeat, as no such association was observed. The reduction
in mutant AR levels in iPSCs may also recapitulate the androgen insen-
sitivity in SBMA patients, who often have features of gynecomastia,
oligospermia, and reduced androgenic alopecia (Rhodes et al., 2009;
Sinclair et al., 2007). The CAG repeat length is predictive of the onset
of disease in SBMA patients, but has not been shown to be related to
the severity of androgen insensitivity.
Our iPSC model system provides the opportunity to evaluate the
relative contribution of speciﬁc cell types to the disease pathogenesis.
An evaluation of the potential for motor neuron differentiation shows
that SBMA iPSCs differentiate into HB9 and Isl1 positive motor neurons
with an efﬁciency similar to controls. The SB18 line with a 68 CAG re-
peat was observed to have a decrease in motor neuron generation,
which was not DHT dependent. This ﬁnding may be limited to the
SB18 line because of its relatively large CAG repeat size. It is possible
that the nuclear AR detected in the vehicle treated neurons (Fig. 3C)
may be masking any differences with DHT treatment. Furthermore,
there is also no reduction in the number of cultured motor neurons
maintained in DHT for 10 days after dissociation in the other patient
cultures. This ﬁnding is consistent with analysis of motor neuron
counts from the spinal cord of SBMA model mice which do not show a
signiﬁcant reduction of motor neuron numbers (Katsuno et al., 2002;
Palazzolo et al., 2009). The ﬁnding that control and SBMAmotor neuron
cultures havewell developed processes that stain for SMI-32, β-tubulin,
and neuroﬁlament suggests that the differentiation potential of the
SBMA motor neuron cells is intact. Our differentiated motor neurons
express AR, although the nuclear signal is not as strong as in other
non-motor neuron cells within the culture. It is interesting that motor
neurons in general also have higher levels of phosphorylated GSK-3β,
as GSK-3β inhibition has been shown to increase nuclear export of the
AR in prostate cancer cell models (Schutz et al., 2011).
Themotor neurons from patient SB6with 62 CAGs and patient SB18
with 68 CAGs had increased acetylatedα-tubulin compared to controls.
The increased acetylation of α-tubulin may be a consequence of
reduced HDAC6 activity. HDAC6 levels were decreased in the SBMA
motor neuron cells from several patient lines, including the iPSC lines
with 51 CAGs. Although a reduction in HDAC6 protein was detected in
motor neuron cultures from patient lines containing 51 CAGs, the
changes in acetylated α-tubulin were seen only in the cultures with
62 and 68 CAGs. It is possible that other changes in the 62 and 68 CAG
lines allowed this alteration to occur. The importance of this HDAC6
Fig. 2. Androgen receptor (AR) expression in iPSCs derived from patients with spinal and bulbar muscular atrophy (SBMA). (A) Immunoﬂuorescence images show that iPSCs treatedwith
dihydrotestosterone (DHT) have increased AR localization in the nucleus compared to iPSCs treated with the ethanol vehicle alone (EtOH). DAPI (blue), Tra 1-60 (green) and AR (red).
Scale bar = 10 μM. (B) Western blot comparing AR in SBMA and control samples treated with EtOH or DHT shows increased AR with DHT. (C) AR levels are decreased in SBMA lines
compared to controls, either with EtOH vehicle alone or with DHT. Insets show representative western blots of AR in EtOH-and DHT-treated iPSCs. n ≥ 3 (D) AR mRNA levels in SBMA
and control cells are similar with or without DHT when measured by quantitative RT-qPCR standardized to GUSB. Error bars represent standard error of the mean n = 3; 2-way
ANOVA, ***p = 0.001, ****p b 0.001.
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Fig. 3. Motor neuron differentiation from iPSCs. (A) Protocol timeline for differentiation of iPSCs, EB = embryoid body, NDM = neuronal differentiation media. (B) Representative
immunoﬂourescent image showing equivalent motor neuron numbers in EtOH- and DHT-treated control and SBMA motor neurons stained for Isl1/HB9 (green) and DAPI (blue).
There is no measurable difference in the percentage of Isl1/HB9 positive motor neurons compared to total cells among the different control and SBMA lines. Scale bar = 40 μM. (C) AR
staining (red) in SBMA and control motor neurons (Isl1/HB9) showing increased AR intensity with DHT treatment (two sets of images with DHT treatment are shown), DAPI (blue).
Scale bar = 10 μM.
17C. Grunseich et al. / Neurobiology of Disease 70 (2014) 12–20down-regulation in the pathogenesis of SBMA is not clear. HDAC6 has
catalytic domains responsible for deacetylating various targets, includ-
ing α-tubulin (Hubbert et al., 2002), HSP-90 (Kovacs et al., 2005),
cortactin (Zhang et al., 2007), and Ku-70 (Subramandian et al., 2011)
as well as a ubiquitin C-terminus hydrolase-like zinc ﬁnger domain,
which can bind to polyubiquitinated midfolded proteins and dynein
motors, allowing for their proper autophagic clearance to aggresomes
(Kawaguchi et al., 2003). HDAC6 deﬁciency has also been reported to
disrupt the organization of the axon initial segment which is important
in preferential concentration of ankyrinG and sodium channels in neu-
rons (Tapia et al., 2010). In addition, HDAC6 may increase AR stability
by deacetylating its chaperone protein HSP-90 (Ai et al., 2009).
HDAC6may also function in the transport of lysosomes to themicro-
tubule organizing center (MOC), as HDAC6 knockdown produces dis-
persion of lysosomes from the MOC. In a study by Iwata et al. (2005),
shRNAmediatedHDAC6 knockdown inHeLa cells resulted in dispersion
of lysosomal LAMP2 staining around the nucleus. The lysosomal stain-
ing pattern detected in this study was similar to what we observed
in SBMA iPSC motor neurons with reduced HDAC6 staining. We also
found that LAMP1, a marker of lysosomes, is hyperglycosylated inthe iPSC-derived SBMA motor neurons. A similar ﬁnding was reported
in myoblast cultures from patients with Paget's disease and
frontotemporal dementia (IBMPFD) (Vesa et al., 2009). In that study,
myoblasts with mutations in the valosin containing protein (VCP)
gene were found to have differential glycosylation of LAMP1 and
LAMP2 and enlarged autophagosomes. iPSC-derived SBMA motor neu-
rons have alterations in lysosomal localization and post-translational
modiﬁcation, which may be a consequence of a disruption in HDAC6
mediated microtubule transport.
HDAC6 has previously been implicated in SBMA, as it was found
to enhance autophagy to compensate for impairment of the ubiquitin–
proteasome system in a Drosophila model (Pandey et al., 2007). In
this model, ectopic expression of either Drosophila or human
HDAC6 rescued the degenerative phenotype caused by polyglutamine
expanded AR. Changes in protein acetylation have also been reported
in a PC12 model of SBMA in which polyglutamine expanded AR was
hyperacetylated compared to normal AR (Montie et al., 2011). Expres-
sion of the deacetylating enzyme SIRT1 protectedmousemotor neurons
expressing the mutant AR, suggesting that AR acetylation may be a
therapeutic target in SBMA.
Fig. 4.α-Tubulin acetylation is increased in SBMA iPSC derivedmotor neurons. (A) Immunoﬂuorescent images showing acetylated tubulin (green) andDAPI (blue) in differentiatedmotor
neurons from a control (NC15) line and lines from two SBMA patients (SB3 and SB6MP2). The line with high repeat length, SB6MP2 (62 CAGs) shows increased acetylation. (B) Images
stained for DAPI (blue), and for acetylated tubulin (green), and neuroﬁlament (red) in control and patient-derived motor neurons from a separate clone (SB6MP3) with 62 CAGs also
shows increased tubulin acetylation. (C) Decreased HDAC6 in an SBMA patient line (SB6), as shown by staining with DAPI (blue), HDAC6 (red) and HB9/Isl1 (green). Phosphorylated
GSK-3β (red) remains unchanged. (D) Relative HDAC6 levels in two control and three SBMA lines, with a representative western blot (n= 3) showing decreased HDAC6 in differentiated
patient and control cellswith staining for ChAT andHB9 shown for comparison. The difference between patient and control lines for quantiﬁcation ofHDAC6 immunoﬂuorescence relative
to Isl1/HB9 is signiﬁcant; n = 3, student's t-test, ****p b 0.001. All scale bars = 40 μM.
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Our study demonstrates several ﬁndings in the SBMA iPSCs that
warrant additional investigation. The ﬁnding that CAG repeat length is
unstable in speciﬁc iPSC lines allows additional study of factors that
may be involved in the expansion or contraction of the repeat. It is pos-
sible that genetic factors in some lines make them more susceptible to
instability, or that factors intrinsic to the reprogramming strategy mod-
ify the instability. SBMA iPSCs appear to havemotor neuron differentia-
tion capacity equivalent to controls, and although no changes in cell
survival could be appreciated it is possible that treatmentwith addition-
al stressors would induce a selective vulnerability. Although increased
acetylated α-tubulin was observed predominantly in cells from two
patients with particularly long repeats, the HDAC6 decrease was also
observed in motor neurons cultured from several others. Decreased
HDAC6 and increased acetylated α-tubulin levels were also seen in an
MN1 cell model of SBMA, and in the spinal cord of an SBMA patient.
Since HDAC6 has been shown to be important for trafﬁcking misfolded
protein to the aggresome, a deﬁciency in HDAC6 may produce a reduc-
tion in autophagic ﬂux, with changes in mitochondrial activity, proteintrafﬁcking, and lysosomal function. Changes in lysosomal localization
were observed in the SBMA motor neurons, and the lysosomal marker
LAMP1 was found to have increased glycosylation. The signiﬁcance of
this glycosylation is not clear at this time, but it appears to indicate
abnormal function of the lysosomal compartment. Further studies may
help to determine howHDAC6 levels are reduced in SBMA and to charac-
terize the consequence of these changes in the disease mechanism.
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then stained for DAPI (blue), acetylated tubulin (green), and HDAC6 (red). Western blot analysis on 24Q and 65Q cells treated with EtOH (vehicle) or DHT for 48 h. There is decreased
HDAC6 and increased acetylated tubulin (n= 4, p= 0.03) in the DHT treated 65Q AR cells compared to treated AR24Q cells. (B) Human spinal cord from a control and an SBMA patient
stained for DAPI (blue), HDAC6 (red), and acetylated tubulin (green), with motor neurons (indicated by arrows) showing decreased levels of diffuse HDAC6 and increased acetylated
tubulin in the SBMA patient. Scale bars = 20 μM.
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